Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002936 · ClinicalTrials.gov registry record · Phase 1

Altretamine and Etoposide in Treating Patients With HIV-Related Cancer

A Phase 1 study, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 1
Development phase

NCT00002936: Completed Phase 1 study, sponsored by Roswell Park Cancer Institute.

NCT00002936 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002936, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating patients with HIV-related cancer.

Interventions

  • DRUG etoposide
  • DRUG altretamine

Trial Details

FieldValue
Start Date 1996-07
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What the finished NCT00002936 record still lists

NCT00002936 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 2 interventions - of which etoposide is the first listed.

NCT00002936 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002936 about?

NCT00002936 is a clinical study titled "Altretamine and Etoposide in Treating Patients With HIV-Related Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of altretamine plus etoposide in treating patients with HIV-related cance...

What is the current status of trial NCT00002936?

This trial is currently completed. It is a Phase 1 study. The study started on 1996-07.

What interventions are being tested in trial NCT00002936?

The interventions under investigation include: etoposide (DRUG), altretamine (DRUG).

Who is sponsoring clinical trial NCT00002936?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002936, the US trial registry maintained by the National Library of Medicine. NCT00002936 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.